Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Newbury Pharmaceuticals AB's share price is €0.1555.
Newbury Pharmaceuticals AB's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 was €0.10. Hence, Newbury Pharmaceuticals AB's PS Ratio for today is 1.50.
Warning Sign:
Newbury Pharmaceuticals AB stock PS Ratio (=2.44) is close to 1-year high of 2.44.
The historical rank and industry rank for Newbury Pharmaceuticals AB's PS Ratio or its related term are showing as below:
FRA:P52'
s PS Ratio Range Over the Past 10 Years
Min: 0.78 Med: 3.31 Max: 69.61
Current: 2.38
During the past 5 years, Newbury Pharmaceuticals AB's highest PS Ratio was 69.61. The lowest was 0.78. And the median was 3.31.
FRA:P52's PS Ratio is ranked better than 52.79% of 951
companies
in the Drug Manufacturers industry
Industry Median: 2.38
vs FRA:P52: 2.38
During the past 5 years, Newbury Pharmaceuticals AB's highest 3-Year average Revenue per Share Growth Rate was 103.50% per year. The lowest was 54.30% per year. And the median was 78.90% per year.
Newbury Pharmaceuticals AB (FRA:P52) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Newbury Pharmaceuticals AB PS Ratio Related Terms
Newbury Pharmaceuticals AB PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newbury Pharmaceuticals AB PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Newbury Pharmaceuticals AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Newbury Pharmaceuticals AB's Share Price of today is €0.1555. Newbury Pharmaceuticals AB's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Newbury Pharmaceuticals AB (FRA:P52) has a PS Ratio of 1.50 as of Aug. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Newbury Pharmaceuticals AB and its competitors. This is 55% below median its historical median of 3.31. Over the past decade, Newbury Pharmaceuticals AB's PS Ratio has ranged from 0.78 to 69.61. According to the industry distribution chart, Newbury Pharmaceuticals AB ranks #449 out of 951 companies in the Drug Manufacturers industry, placing it in the top 47.2%.
Is Newbury Pharmaceuticals AB's PS Ratio too high?
Newbury Pharmaceuticals AB's current PS Ratio of 1.50 is 55% below median its 10-year median of 3.31. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 69.61. The Drug Manufacturers industry median PS Ratio is 2.38. Newbury Pharmaceuticals AB's value of 1.50 is 37% below this industry median. Based on the distribution chart, Newbury Pharmaceuticals AB ranks #449 out of 951 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Newbury Pharmaceuticals AB ranks #449 out of 951 companies for PS Ratio. This puts Newbury Pharmaceuticals AB in the upper half of its industry. The industry median PS Ratio is 2.38. Newbury Pharmaceuticals AB's value of 1.50 is 37% below this benchmark. Historically, Newbury Pharmaceuticals AB's own PS Ratio has ranged from 0.78 to 69.61 over the past decade. While the company's 10-year median is 3.31 vs. the industry median of 2.38, Newbury Pharmaceuticals AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.38, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Newbury Pharmaceuticals AB's current PS Ratio of 1.50 is 37% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Newbury Pharmaceuticals AB and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current PS Ratio is 1.50, which is 55% below median its own 10-year median of 3.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Newbury Pharmaceuticals AB (FRA:P52) has a current PS Ratio of 1.50. The stock's GF Value™ is €0.20, compared to a current price of €0.16 — trading 22.3% below its estimated fair value. The current PS Ratio is 1.50, which is 55% below median its 10-year median of 3.31 and 37% below the Drug Manufacturers industry median of 2.38. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (FRA:P52), the current PS Ratio is 1.50 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (FRA:P52) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of €0.16 is trading 22.3% below its estimated GF Value™ of €0.20.
Key valuation signals for FRA:P52:
PS Ratio: 1.50 (55% below median its 10-year median of 3.31)
GF Value™: €0.20 vs. price of €0.16 (22.3% below fair value)
Industry Position: 37% below the Drug Manufacturers median (#449 of 951)
No single metric tells the full story. See the FRA:P52 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score
Get the complete analysis for FRA:P52
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:P52 has been successfully added to your 
